Refine your search

Search Results within category "Neurology"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Neurology"


45 Study Matches

Memory and Aging Study

This research is being done to find out more about changes in the brain as we age and to determine if MRI, genetic (DNA) variations, and neuropsychological tests can be used to evaluate memory loss and cognitive impairment.
Lauren Spreen at lspreen@pennstatehealth.psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Alzheimer's disease
Diagnosis of Mild Cognitive Impariment
Normal Controls-Cognitively normal functioning
Exclusion Criteria:
Neurological disease (e.g., stroke, tumor, Parkinson's disease, etc.)
Psychiatric disorder (e.g., bi-polar, schizophrenia, etc.)
History of chemotherapy
Presence of a cold or viral infection
Presence of a pacemaker, aneurysm clips, or any metal in body
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Crest-2: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial

To assess if the proportion of patients with a primary event differs between patients treated with intensive medical management alone compared to CEA, or to CAS, in patients with high grade asymptomatic carotid stenosis. To assess whether intensive medical management differs from CEA and from CAS to maintain the level of cognitive function at 4 years of follow up To assess if there are treatment differences in major stroke, minor stroke, disabling stroke and tissue based stroke at 4 years, using an analytic approach identical to that for the primary aim. To assess if the CEA or CAS versus intensive medical management difference is affected by patient age, sex, severity of carotid stenosis, restenosis, risk factor level and during of the asymptomatic period
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02089217
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age >/=35 years
Do you have documented stenosis of your carotid?
Have you had any neurologic symptoms on the same side as your stenosis
No medical history of stroke or TIA on the same side as the stenotic vessel in the previous 180 days
If female, not pregnant
Exclusion Criteria:
Prior stroke with residual disability
Symptomatic ICH within past 12 months
Chronic afib
Ejection fraction < 30%
Do you use an anticoagulant? What medication?
Heart & Vascular, Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Deprexis Study: An online program to reduce depression in MS – a phase III international multicenter randomized controlled trial

An online program to reduce depression in MS – a phase III international multicenter randomized controlled trial
Deprexis Team Roman at mhc147@psu.edu or 814-865-5578
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02740361
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Multiple Sclerosis
Current Depression
No current treatment for depression
Internet access
Between the ages of 18-65
Exclusion Criteria:
No diagnosis of MS
No current psychotherapy for depression
No substantial neurocognitive impairments
Started anti-depressants in the last 2 months
Neurology, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Tongue movement in adults with motor speech disorder

Tongue movement in adults with motor speech disorder
Jimin Lee at jxl91@psu.edu or 814-863-5338
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
be a native speaker of American English
have normal hearing
between 18 and 40 years of age
have no known speech, language, learning or neurological disorders
have very little experience in communicating with people that have motor speech disorders
Exclusion Criteria:
younger than 18 years of age; older than 40 years of age
Not a speaker of American English only
With hearing impairment
have neurologic and/or speech/language disorders
have extensive experience in communicating with people that have motor speech disorders
Neurology, Muscle & Bone, Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 2 locations

Study Locations

Hide all locations
Location
Hershey, PA
State College, PA

Asymmetric neurodegeneration of central olfactory system in early-stage Parkinson’s disease

This research is being done to study the deterioration of the central olfactory system (sense of smell system) in the brains of patients diagnosed with H&amp;Y stage 1 or 2 Parkinson’s disease compared to that of healthy volunteers.
Lauren Spreen at lspreen@pennstatehealth.psu.edu or 717-531-5857
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Cognitively-normal H&Y stage 1 PD patients. A physician-documented parkinsonian symptom onset between the ages of 40-59. 1st visit prior to age 65. PD stage I diagnosis must be documented for a min of 2 years.
Cognitively-normal H&Y stage 2 PD patients. H&Y stage 2, as defined by an exam in the practically defined “off” state, and have a diagnosis of PD at the age of 59 or younger. 1st visit prior to age 65
Healthy participants between ages 40-64 at their first visit.
Able and willing to provide informed consent
Fluent in written and spoken English
Exclusion Criteria:
Parkinson-plus syndrome
Dementia
Previous antipsychotic or anti-dopamine drug therapy
Traumatic head injury
Other neurological diseases or disorders
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction

This is a Phase 3 study, which means that BIIB093 (study drug) has already been investigated in previous clinical research studies with a small number of people with large hemispheric infarction (LHI). These studies suggested that the study drug was safe, did not cause serious side effects or discomfort, and may reduce brain swelling, disability, and death in subjects with LHI. In this study, we want to investigate the study drug in a larger number of subjects (hundreds) to know more about it. LHI is a type of stroke. An ischemic stroke occurs when blood flow to parts of the brain is blocked, such as by a blood clot. This can cause damage to the brain. In LHI a large portion of the brain is damaged. People who have LHI can develop swelling of the brain called cerebral edema, which can worsen the symptoms and outcomes of LHI. Currently, there are no medications available to specifically reduce brain swelling caused by LHI. In this study, we want to investigate how well the study drug works to improve functional outcomes (the ability to do normal daily activities, such as walking and getting dressed) in subjects with LHI. This study will also look at the long-term effects of the study drug over time and see how safe the study drug is.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02864953
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A clinical diagnosis of acute ischemic stroke in the MCA territory within 10 hours of symptom onset
Aged 18 to 85 years old, inclusive, at the time of informed consent
Screening NIHSS ≥10
Exclusion Criteria:
In the judgment of the Investigator, the subject is likely to have supportive care withdrawn in the first day
Commitment to decompressive craniectomy (DC) prior to enrollment
Evidence (clinical or imaging) of concurrent infarction in the contralateral hemisphere deemed by the Investigator to be sufficiently serious so as to affect functional outcome
Clinical signs of herniation and/or loss of other brain stem reflexes, attributable to edema or herniation according to the Investigator’s judgment
Brain hemorrhage (other than small petechial/punctate hemorrhages) on NCCT/MRI
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Physical Therapists Role in Promoting Physical Activity for People with Chronic Physical Disabilities

We plan to conduct a qualitative study exploring perspectives of physical therapists and people with disability regarding physical activity promotion
Jacob Corey at jjc6062@psu.edu or 814-865-1691
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years of age
Fluent in english
Individual with a physical disability (eg. limb amputation, spinal cord injury, spinabifida, cerebralpalsy, arthritis, motor impairment)
Has participated in physical therapy in the last year
Exclusion Criteria:
Under the age of 18
Does not speak fluent english
does not have a physical disability
Has not participated in physical activity in the last year
Arthritis & Rheumatic Diseases, Neurology, Muscle & Bone
  Email this study information to me
  Contact the study team

Neural Correlates of Cognitive Dysfunction in Postural Tachycardia Syndrome

Postural tachycardia syndrome (POTS) is a chronic syndrome in which the heart beats too quickly when standing. POTS primarily affects young women. People with POTS also experience symptoms such as feeling faint, fatigue, nausea, and mental clouding or "brain fog." “Brain fog” is one of the most bothersome symptoms of POTS and it is unknown why people with POTS experience this symptom. Some studies have shown that POTS patients have problems with attention, memory and executive function (ability to plan, organize information, and adapt to changes) while seated and when upright. In this study, we will evaluate how brain function during mental tasks is affected in people with POTS compared to healthy volunteers. All volunteers will complete mental tasks while lying down and standing. If eligible, we will measure brain activity using functional magnetic resonance imaging (fMRI).The findings from this study will increase our understanding of the mental complaints in people with POTS, to hopefully help with development of new treatments.
Amanda Miller at aross1@pennstatehealth.psu.edu or 717-531-7676
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT04137757
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Men and women of all races
18- 60 years old
Previously Diagnosed with POTS or healthy people without chronic illness
Capable of giving informed consent
Exclusion Criteria:
Age <18 years or >60 years
Pregnant or breastfeeding women
Other potential causes for tachycardia (e.g. prolonged bed rest, dehydration)
Taking stimulant medications within the past 3 months as these may alter cognition
Unable to tolerate an MRI scanner (e.g. claustrophobia, implanted metal)
Heart & Vascular, Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

The primary purpose of this phase 3 clinical trial is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03920293
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosed with myasthenia gravis for at least 6 months
Myasthenia Gravis Foundation of America (MGFA) classification: Class II to IV
Weigh at least 40 kg (about 88 lbs)
Exclusion Criteria:
History of thymectomy (removal of the thymus gland) within 12 months
Active or untreated thymoma (tumor of the thymus gland)
History of meningococcal infection
HIV infection
Pregnancy
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Muscular Dystrophy Association Neuromuscular Observational Research (MOVR) Data Hub Protocol

The Muscular Dystrophy Association (MDA) wants to collect information about individuals with neuromuscular disease to better understand the disease progression and ultimately improve the medical care, quality of life, and survival of those with neuromuscular disease. To collect this information, MDA has created a data registry called the Neuromuscular Observational Research Data Hub (referred to as the “MOVR Data Hub”). The MOVR Data Hub is a kind of database — a way of collecting and storing information.
All
All
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosed with a neuromuscular condition
Exclusion Criteria:
Unwilling to provide informed consent
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Predicting Concussion Outcomes with Salivary miRNA

The purpose of this study is to identify changes in salivary micro ribosomal nucleic acid (miRNA) expression that are predictive of symptom duration and severity following mild traumatic brain injury (mTBI) in children. The primary endpoints of this study are as follows: 1) Characterization of brain-related miRNA in the saliva of 250 children with mTBI and 200 age- and gender-matched controls between the ages of five and twenty-three years. 2) Identification of a set of salivary miRNAs that is predictive of duration and severity of mTBI symptoms.
Jessica Beiler at jbeiler@pennstatehealth.psu.edu
All
All
This study is also accepting healthy volunteers
NCT02901821
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
5 to 23 years of age
Seen in the Penn State Pediatric Concussion Clinic within 2 weeks of most recent concussion
Exclusion Criteria:
Does not speak english
Periodontal disease
Ongoing seizure disorder, or other neurologic disorder
Drug or alcohol dependency
clinical diagnosis of severe TBI
Children's Health, Neurology, Sports Medicine
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy

This is a multi-site, placebo-controlled, double-blind, time to intervention study designed to evaluate the clinical efficacy and safety of droxidopa versus placebo over a 12-week double-blind treatment period in patients with symptomatic NOH who have previously received up to 16 weeks of open-label treatment with an individually optimized dose of droxidopa (randomized withdrawal design).
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02586623
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Symptomatic neurogenic orthostatic hypotension associated with: (1) primary autonomic failure (Parkinson’s Disease, Multiple System Atrophy, Pure Autonomic Failure), (2) Non-Diabetic Autonomic Neuropathy, or (3) Dopamine Beta Hydroxylase deficiency
Able to stand, with or without limited assistance
Exclusion Criteria:
History of heart attack within the past 2 years, congestive heart failure (class 3 or 4), or uncontrolled cardiac arrhythmia
High blood pressure that requires treatment with blood pressure medication
History of cancer within the past 2 years (some exceptions can be discussed)
Diabetic autonomic neuropathy
Women who are pregnant or breastfeeding
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Monetary Reward Processing and Emotion Regulation in Adolescence: An fMRI pilot Study

This research is being done to identify patterns of brain activation underlying monetary reward processing and emotion regulation in adolescence, as well as correspondence between parent and adolescent neural activation. Children and their parents will complete questionnaires. Children will complete computer tasks during EEG and in an MRI scanner. Parents can also complete the MRI scan if interested.
All
Younger than 18 years old
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 12--16 years
Fluent in English
No history of treatment for psychiatric disorders
Exclusion Criteria:
Intellectual or developmental disabilities
Visual or hearing impairments
Inability to complete MRI scan due a pacemaker, aneurysm clips or any metal in body (e.g., braces, surgical devices)
Currently pregnant or lactating
Neurological disease (e.g., stroke, tumor, Parkinson’s disease, etc.)
Children's Health, Neurology, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Experimental determination of the neurogenic contribution to skin flowmotion

The purpose of this study is to use spectral analysis to measure blow flow changes in superficial vessels of the arm. This study will explore how skin blood flow changes in response to heat and nerve inhibition. We will be locally heating the skin and blocking nerves of the skin with a topical numbing cream and measuring the resulting skin blood flow. Skin blood flow is measured by a machine that shines a harmless laser light onto the skin. The machine produces a signal that looks like a wave moving up and down. There is a known, and previously used, algorithm that can identify the neurogenic input-wave from the total skin blood flow-wave.
Zachary Lichter at zzl5229@psu.edu or 814-863-8557
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Men and women aged 18-85
English speaking individuals
Exclusion Criteria:
individuals diagnosed cardiovascular, metabolic, or dermatological conditions
nicotine use (e.g. smoking, chewing tobacco, etc)
pregnancy or breastfeeding
illicit or recreational drug use
allergies to lidocaine or prilocaine
Heart & Vascular, Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A phase 3 double-blind randomized study to assess the efficacy and safety of intravenous ATB200 co-administered with oral AT2221 in adult subjects with late-onset Pompe disease compared with alglucosidase alfa/placebo

The goal of this study is to compare the effectiveness of a new combination treatment, called ATB200 and AT2221, with your current medication, called Lumizyme®/Myozyme®, or alglucosidase alfa. The purpose is to see how the treatments compare in treating Pompe disease.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03729362
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18-76 years old
weigh at least 50 kg or 110 lbs
diagnosed with Pompe disease
breathing capacity (FVC) within 30% to 80% of predicted normal
able to walk at least 150 meters in 6 minutes
Exclusion Criteria:
use of invasive or noninvasive ventilatory support > 6 hours per day while awake
pregnant or breastfeeding or planning to become pregnant
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

The purpose of this study is to learn about the safety and effectiveness of amifampridine phosphate in people with myasthania gravis (MG).
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03304054
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of MG as Class II to Class IV
positive serologic test for anti-MuSK antibodies or anti-AChR antibodies
Exclusion Criteria:
Have epilepsy
Have a long QT syndrome
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Interlimb differences in Motor Control and Learning

This study examines how each brain hemisphere contributes to motor control and coordination. Participants play virtual reality/computer games to look at how their arms move during different activities.
Brooke Fosaaen at sainburglab@psu.edu or 814-865-7937
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
over the age of 18
Exclusion Criteria:
neurological disease
upper-extremity orthopedic injuries that interfere with participation
Neurology, Sports Medicine, Muscle & Bone
  Email this study information to me
  Contact the study team
  Show all 2 locations

Study Locations

Hide all locations
Location
Hershey, PA
State College, PA

Characterization of Agrin/LRP4 Antibody Positive Myasthenia Gravis

This study will evaluate new autoantibodies that might explain symptoms in patients with double negative myasthenia gravis (DNMG). If these newly identified autoantibodies are associated with different subtypes of MG, being able to test for them will allow clinicians to have a biomarker that will identify patients with these subsets of MG.
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosed with myasthenia gravis AND negative for myasthenia gravis-related antibodies OR
Diagnosed with another neuromuscular disorder that is not myasthenia gravis OR
Not diagnosed with any neuromuscular disorder
At least 21 years old
Exclusion Criteria:
Received IVIG treatments within the last 6 weeks
Received plasma exchange withing the last 6 weeks
Received treatment with rituximab within the last 24 weeks
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Real-world Older Driving Study (ROADS)

ROADS will examine the relationships between driving, health, psychosocial and cognition in healthy older adults. This study will involve the placement of a video recording device in participants’ vehicles for 3 months. These devices will record driving habits and conditions such as speed and braking. Participants will also be asked to complete daily surveys on a study provided phone throughout the 3 month study. ROADS participants will be asked to visit the Penn State University for 3 in person visits to complete questionnaires, cognitive and health assessments, and to learn how to use the study provided phone. These visits may last up to 3 hours and on a rare occasion slightly longer.
Michelle Huerbin at mlh5955@psu.edu or 814-865-4773
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 70-95 years
Have a valid US driver's license
Drive on average 3 days a week
Willing to have camera installed in vehicle for 3 months
Exclusion Criteria:
Alzheimers or dementia
Any reason for driving restrictions
Neurology, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Site for Therapy in Amyotrophic Lateral Sclerosis (TAME)

This is a phase IIB multi-centered, double blind, placebo controlled study to assess the safety and efficacy of a medication called memantine in people with ALS. This study is designed to validate the preliminary data that suggests memantine can slow down the course of ALS and also to determine if memantine can improve ALS patients who have characteristics of frontotemporal dementia.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02118727
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-85
Diagnosed with amyotrophic lateral sclerosis (ALS)
ALS Functional Rating Scale (ALSFRS-R) score > 25
Has a caregiver willing to help with study activities
Exclusion Criteria:
Forced vital capacity (FVC) ≤ 60% predicted
ALS-related weakness for more than 3 years
History of liver disease
Kidney failure
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Brain Mechanisms of Overeating in Children

Reducing intake from large portions is of critical importance to preventing obesity. People consistently eat more when they are served larger portions, a phenomenon known as the portion size effect. The mechanisms of the portion size effect are not well understood, and investigating the underlying neurobiology that drives this phenomenon may inform the development of more effective obesity prevention programs. The proposed research will follow healthy weight children who vary by family risk for obesity to identify the neurobiological and appetitive traits that are implicated in overeating and weight gain during the critical pre-adolescent period. We expect results to confirm the hypothesis that reduced function of brain inhibitory pathways and increased activity in brain reward pathways in response to portion size cues contributes to excess intake with large portions and greater weight gain over time, particularly in children who have higher risk for obesity. The proposed studies will characterize the relationship between brain response to portion size and eating behavior and will allow us to determine whether brain and behavioral responses predict body fat gain during pre-adolescence. These studies will contribute essential information to our understanding of the pathways implicated in overeating and obesity and will facilitate the characterization of “at risk” phenotypes that can be targeted by prevention programs.
Kara Hickok at kih5334@psu.edu or 814-865-5169
All
Younger than 18 years old
This study is also accepting healthy volunteers
NCT03341247
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
The child must be age 7-8 when the first study visit is completed
The child must not have any food allergies to foods used in the study, learning disabilities, psychological diagnoses, red/green color blindness, or claustrophobia.
The child must not be taking any medications known to influence cognitive function, taste, appetite or blood flow
The child's BMI must be below the 90th percentile at the first visit
The biological mother and father must have a BMI between 18.5-25 kg/m2 (low-risk group) or greater than or equal to 30 kg/m2 for mothers and greater than or equal to 25 kg/m2 for fathers (high-risk group) and 1 parent must attend all visits.
Exclusion Criteria:
Children will be excluded if they are not within the age requirements (< than 7 years old or > than 8 years-old at the first visit).
Children will be excluded if they have any food allergies, learning disabilities, psychological diagnoses, red/green color blindness, or claustrophobia
Children will be excluded if they are taking cold or allergy medication, or other medications known to influence cognitive function, taste, appetite, or blood flow
Children will be excluded if their BMI is above the 90th percentile at the first visit
Families will be excluded if the biological mother or father do not fit the BMI requirements
Food & Nutrition, Prevention, Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Long-Term Nicotine Treatment of Mild Cognitive Impairment

The purpose of this study is to determine whether nicotine can improve symptoms of memory loss in people experiencing mild memory problems (referred to in this study as “mild cognitive impairment” or MCI). Recent studies have suggested that one of the causes of memory disorders may be a reduction in a particular chemical substance in the brain. This chemical substance, acetylcholine, is thought to act on certain brain cells in a specific way that helps us to remember and use memories as well as affect our attention. In people with MCI (and Alzheimer’s disease), the level of acetylcholine may be changed, and this may impair brain functioning. Preliminary studies have suggested that short-term administration of nicotine appears to improve memory in patients with mild memory loss and early Alzheimer’s disease (AD). It has been known for many years that nicotine imitates many of the actions of acetylcholine. By administering nicotine over a longer period of time to participants with MCI, we hope to better understand whether nicotine may act to improve memory loss symptoms over the longer term and whether it may help to delay the progression of memory loss symptoms. The amount of nicotine in each patch used in this study is the same as patches that are FDA approved for use in people who are trying to quit smoking.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02720445
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patient must have a subjective memory concern as reported by patient, study partner, or clinician
Age 55-90 (inclusive)
Study Partner is available who has frequent contact with the patient (e.g. an average of 10 hours per week or more), and can accompany the patient to most visits to answer questions about the patient
Must speak English fluently
Good general health with no additional diseases/disorders expected to interfere with the study
Exclusion Criteria:
Any use of tobacco or nicotine products within the past year
Any significant neurologic disease such as Alzheimer’s disease dementia, Parkinson’s disease, multi-infarct dementia, brain tumor, seizure disorder, etc.
History of alcohol or substance abuse or dependence within the past 2 years
Men's Health, Neurology, Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Pilot Study to evaluate the pharmacokinetic, pharmacodynamic, and resistance profile to trametinib and dabrafenib in BRAF-V600E mutated recurrent gliomas

This research is being done to understand how much of two drugs (dabrafenib and trametinib) is able to enter brain tumors and how well the drugs are able to turn off this pathway in brain tumors. The study will also look at how tumors lose sensitivity to this treatment. People with primary brain tumors who are already taking dabrafenib and trametinib and who need a brain surgery are eligible for this study. Biospecimens (tissue, blood, and cerebrospinal fluid (CSF)) taken during the surgery will help us understand how much of these two study drugs actually get into the brain, their effect, and how the tumors become resistant to treatment.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years old
Subjects must have a history of primary brain tumor (including but not limited to glioblastoma (GBM), anaplastic astrocytoma (AA), anaplastic ganglioglioma (AG), and anaplastic pleomorphic xanthoastrocytoma (PXA)).
Subjects must have a BRAF-V600 mutation identified in previous tissue analysis (may be IHC or PCR based). Allowable mutations include V600E, V600K, V600R, and V600D.
Subjects must be taking dabrafenib at a dose of at least 50mg twice daily (adults only) and / or trametinib at a dose of at least 1mg daily (adults only) for at least 7 days prior to surgery as prescribed by their treating physician.
Subjects must be undergoing surgery for clinical purposes
Exclusion Criteria:
Younger than 18 year old
Subjects who are receiving any other investigational agents or chemotherapeutic agents.
Neurology, Cancer
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

PA CURE Phase 1: Biomarkers of Traumatic Brain Injury (TBI)

The study seeks to identify the characteristics of brain function after traumatic brain injury (TBI). The data obtained through this study aims to help physicians better understand the characteristics of specific products released into the blood and cerebrospinal fluid (CSF) following a TBI, called biomarkers. In addition, we will store blood and CSF samples for later testing as new information becomes available. The long-term goal of this study is to provide physicians with the tools they need to diagnose brain injuries. This information may help doctors judge how severe a head injury is, if treatment needs to be adjusted, and it may help predict how well a patient recovers from the injury.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Traumatic brain injury within the preceding 24 hours requiring admission to the ICU
Current age 18-60 years
Head CT with acute intracranial pathology
Ability to undergo MR and PET imaging
Exclusion Criteria:
Penetrating TBI due to gunshot wound, shrapnel, or other metallic substance that would preclude patient from undergoing MR imaging
Pre-existing neurologic or neurodegenerative disorder or history of psychiatric conditions, such as major depressive disorder or psychosis
Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with neuropsychological testing
Contra-indication to MR imaging, such as ferrous metal, pacemakers, body weight above 125 kg, or concerns about claustrophobia
Non-native English speakers (translations are not available/validated for most neuropsychological test measures).
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Interactions between the olfactory, auditory, visual, and trigeminal systems

The purpose of this study is to use fMRI to identify and characterize the olfactory, auditory, visual and trigeminal-related brain networks. This research will then be use to enhance human health by laying the foundation to develop sensitive biomarkers to identify people who are at risk of developing brain disorders such as Alzheimer’s disease and Parkinson’s disease, where olfactory deficits are known preclinical symptoms.
Michelle Douthitt at mld43@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy subjects (non-synesthetic) with normal olfactory, visual, and hearing abilities
Healthy subjects (synesthetic) with normal olfactory, visual, and hearing abilities
Clear sinuses
Exclusion Criteria:
Non-English speaking
Pregnant or lactating
Presence of a pacemaker, aneurysm clips or any metal in the body
A history of welding, grinding, and or claustrophobia
Neurological disease (stroke, tumor, Parkinson's) or Psychiatric disorder (bipolar, schizophrenia, etc)
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Abdominal Binders to Compensate for Neurogenic Restrictive Lung Disease in Adults with Spinal Cord Injury

This research is being done to find out if the use of abdominal binders improves lung function, phonation (vocal sounds), and singing in individuals with SCI.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Cervical or Thoracic Spinal Cord Injury
Ages 18-75
ASIA A or B
Exclusion Criteria:
Ventilator dependent
Cystic Fibrosis
COPD
Lung Disease & Asthma, Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

CLadribine tablets: Observational evaluation of effectIveness and patient-reported outcomes (PROs) in suboptimally Controlled patients previously taKing injectable disease-modifying drugs (DMDs) for relapsing forms of Multiple Sclerosis (RMS) (CLICK-MS)

The purpose of this study is to understand how well multiple sclerosis (MS) patients respond to a drug to help with relapsing MS (RMS), This is an oral drug called Cladribine. An observational study is research that aims to collect data over time on how a certain treatment is used and its effects, without any change to your normal care. This means that routine clinical practice is followed. Any treatment given follows your normal routine and is decided by you and your doctor. This study will not alter or interfere with the normal care you receive in any way.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03933215
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Have diagnosis of relapsing multiple sclerosis (RMS)
Have experienced suboptimal response (lack of effectiveness, intolerability, poor adherence) to injectable disease-modifying drug treatment
Exclusion Criteria:
Patients who do not have relapsing multiple sclerosis (RMS)
Patients who are doing well on injectable disease-modifying drugs
Patients who have previously been treated with cladribine in any form
Pregnant or breastfeeding women, women who plan to become pregnant or men whose partner plans to become pregnant during study
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to test if an experimental drug called edaravone is safe and well tolerated in patients with ALS. In this study, you will receive an oral form of edaravone (a liquid solution that you will swallow). This oral formulation is considered experimental, as it has not been approved to treat ALS. The IV (intravenous) form of edaravone has been approved as a treatment for ALS. The IV form was approved in 2017 by the U.S. Food and Drug Administration (“FDA”). It is known by its commercial-brand name, Radicava, and its generic name, edaravone.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04165824
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-75
Forced vital capacity ≥ 70% predicted
ALS symptom onset within 3 years
Exclusion Criteria:
Undergoing treatment for cancer
Pregnancy or lactation
Hereditary fructose intolerance
Unable to take medications orally
History of hypersensitivity to edaravone
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Atrophy of Olfactory Bulb in Early-stage Parkinson’s disease

This research is being done to study the deterioration of the central olfactory system (sense of smell system) in the brains of patients diagnosed with early- stage Parkinson’s disease.
Jianli Wang at jwang2@pennstatehealth.psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A physician-documented parkinsonian symptom onset between the ages of 40-59 will
Patients should not have reached their 65th birthday.
Patients that have tremor, rigidity, and bradykinesia unilaterally
Exclusion Criteria:
Dementia
Autonomic dysfunction
Parkinson-plus syndrome
Postural instability
History of exposure to substances that cause parkinsonism
Neurology
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Fabry Registry

The Registry is a multi-center, international, longitudinal, observational program for patients with Fabry disease that was designed to track the natural history and outcomes of patients. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research-related purposes. The long-term program will proceed for a minimum of 15 years.
All
All
This study is NOT accepting healthy volunteers
NCT00196742
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Have Fabry Disease
Be willing an able to provide written informed consent
Exclusion Criteria:
None
Neurology
  Email this study information to me
  Contact the study team
  See more information